|
Preclinical Studies
Cancer is the second overall
cause of death in the U.S. and many unmet needs exist within the field.
Side effects from chemotherapy treatment are prevalent and
such toxicities not only can prevent a patient from receiving the
most effective chemotherapeutic dose, they can also adversely impact
a patient’s quality-of-life. Additionally,
in areas such as primary liver cancer, standard chemotherapeutic regimens
do not exist. In other areas
such as pancreatic cancer, standard regimens exhibit low response
rates.
PhytoCeutica’s research
and development efforts are focused on seeking solutions to these
unmet needs. PhytoCeutica believes
that
traditional Chinese medicines (TCM), containing up to thousands of phytochemicals
that synergistically act upon multiple targets and biological pathways,
represent the next stage in oncology therapeutics.
These botanical drugs, to be developed as FDA-approved prescription
medicines, can be administered alone or in combination with current
chemotherapies and will meet rigorous preclinical, clinical, and quality-control standards.
PhytoCeutica’s leading
patented
drug candidate. It has
been shown in preclinical studies to have the dual effect of reducing
the toxic effects of chemotherapy as well as potentiating that chemotherapy’s
antitumor effect.
PhytoCeutica is also evaluating two other pipeline products: PHY626 and PHY808/PHY818. PHY808/PHY818 is a single herb that by itself exhibits both a wide spectrum of anticancer activity as well as anti-inflammatory activity, including in rheumatology. Another single herb, PHY626 demonstrates effectiveness in relieving myelosuppression caused by chemotherapy in mouse xenografts. |
|
PhytoCeutica, Inc. 5 Science Park, Suite
13 New Haven, CT 06511
Phone: 203-777-3462 Fax: 203-777-3538 E-mail: info@phytoceutica.com |
|
> Preclinical Studies Home ___________________________________________________ >
PHY906 > PHY626 > PHY808/PHY818 _____________________________________________ >
Traditional Chinese Medicine _____________________________________________ |
